Skip to main content
Erschienen in: Diabetologia 6/2014

01.06.2014 | Article

Association of blood glucose control and pancreatic reserve with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT)

verfasst von: Nasrin Azad, Lily Agrawal, Nicholas V. Emanuele, Ronald Klein, Gideon D. Bahn, Peter Reaven, and The VADT Study Group

Erschienen in: Diabetologia | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

The aim of this study was to test the hypothesis that intensive glycaemic control (INT) and higher plasma C-peptide levels in patients with poorly controlled diabetes would be associated with better eye outcomes.

Methods

The incidence and progression of diabetic retinopathy (DR) was assessed by grading seven-field stereoscopic fundus photographs at baseline and 5 years later in 858 of 1,791 participants in the Veterans Affairs Diabetes Trial (VADT).

Results

After adjustment for all covariates, risk of progression (but not incidence) of DR increased by 30% for each 1% increase in baseline HbA1c (OR 1.3; 95% CI 1.123, 1.503; p = 0.0004). Neither assignment to INT nor age was independently associated with DR in the entire cohort. However, INT showed a biphasic interaction with age. The incidence of DR was decreased in INT participants ≤55 years of age (OR 0.49; 95% CI 0.24, 1.0) but increased in those ≥70 years old (OR 2.88; 95% CI 1.0, 8.24) (p = 0.0043). The incidence of DR was reduced by 67.2% with each 1 pmol/ml increment in baseline C-peptide (OR 0.328; 95% CI 0.155, 0.7; p = 0.0037). Baseline C-peptide was also an independent inverse risk factor for the progression of DR, with a reduction of 47% with each 1 pmol/ml increase in C-peptide (OR 0.53; 95% CI 0.305, 0.921; p = 0.0244).

Conclusions/interpretation

Poor glucose control at baseline was associated with an increased risk of progression of DR. INT was associated with a decreased incidence of DR in younger patients but with an increased risk of DR in older patients. Higher C-peptide at baseline was associated with reduced incidence and progression of DR.
Literatur
1.
Zurück zum Zitat U.S. Department of Health and Human Services, Centers for Disease Control and Prevention (2011) National estimates and general information on diabetes and pre-diabetes in the U.S. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, GA U.S. Department of Health and Human Services, Centers for Disease Control and Prevention (2011) National estimates and general information on diabetes and pre-diabetes in the U.S. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, GA
2.
Zurück zum Zitat Kostev K, Rathmann W (2013) Diabetic retinopathy at diagnosis of type 2 diabetes in the UK: a database analysis. Diabetologia 56:109–111PubMedCrossRef Kostev K, Rathmann W (2013) Diabetic retinopathy at diagnosis of type 2 diabetes in the UK: a database analysis. Diabetologia 56:109–111PubMedCrossRef
3.
Zurück zum Zitat Ko F, Vitale S, Chou CF, Cotch MF, Saaddine J, Friedman DS (2012) Prevalence of nonrefractive visual impairment in US adults and associated risk factors, 1999–2002 and 2005–2008. JAMA 308:2361–2368PubMedCrossRef Ko F, Vitale S, Chou CF, Cotch MF, Saaddine J, Friedman DS (2012) Prevalence of nonrefractive visual impairment in US adults and associated risk factors, 1999–2002 and 2005–2008. JAMA 308:2361–2368PubMedCrossRef
4.
6.
Zurück zum Zitat The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986CrossRef The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986CrossRef
7.
Zurück zum Zitat UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). Lancet 352:837–853CrossRef UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). Lancet 352:837–853CrossRef
8.
Zurück zum Zitat Duckworth W, Abraira C, Moritz T et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129–130PubMedCrossRef Duckworth W, Abraira C, Moritz T et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129–130PubMedCrossRef
9.
Zurück zum Zitat Abraira C, Duckworth W, McCarren M et al (2003) Design of the cooperative study on glycemic control and complication in diabetes mellitus type 2: Veterans Affairs Diabetes Trial (VADT). J Diabetes Complicat 7:314–322CrossRef Abraira C, Duckworth W, McCarren M et al (2003) Design of the cooperative study on glycemic control and complication in diabetes mellitus type 2: Veterans Affairs Diabetes Trial (VADT). J Diabetes Complicat 7:314–322CrossRef
10.
Zurück zum Zitat Faber OK, Binder C, Markussen J et al (1978) Characterization of seven C-peptide antisera. Diabetes 27(Suppl l):170–177PubMedCrossRef Faber OK, Binder C, Markussen J et al (1978) Characterization of seven C-peptide antisera. Diabetes 27(Suppl l):170–177PubMedCrossRef
11.
Zurück zum Zitat Emanuele N, Moritz T, Klein R, The VADT Study Group (2009) Ethnicity, race, and clinically significant macular edema in the Veterans Affairs Diabetes Trail (VADT). Diabetes Res Clin Pract 86:104–110PubMedCrossRef Emanuele N, Moritz T, Klein R, The VADT Study Group (2009) Ethnicity, race, and clinically significant macular edema in the Veterans Affairs Diabetes Trail (VADT). Diabetes Res Clin Pract 86:104–110PubMedCrossRef
12.
Zurück zum Zitat Emanuele N, Klein R, Mortiz M et al (2009) Comparison of dilated fundus examination by ophthalmologists, with 7-field stereo photographs in the VADT. J Diabetes Complicat 23:323–329PubMedCrossRef Emanuele N, Klein R, Mortiz M et al (2009) Comparison of dilated fundus examination by ophthalmologists, with 7-field stereo photographs in the VADT. J Diabetes Complicat 23:323–329PubMedCrossRef
13.
Zurück zum Zitat Chew EY, Bethesda MD, Ambrosius WT et al (2010) The ACCORD Study Group and ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 363:233–244PubMedCrossRef Chew EY, Bethesda MD, Ambrosius WT et al (2010) The ACCORD Study Group and ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 363:233–244PubMedCrossRef
14.
Zurück zum Zitat Patel A, MacMahon SD, Chalmers J et al (2008) The Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572PubMedCrossRef Patel A, MacMahon SD, Chalmers J et al (2008) The Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572PubMedCrossRef
15.
Zurück zum Zitat Beulens JWJ, Patel A, Vingerling JR et al (2009) Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetologia 52:2027–2036PubMedCrossRef Beulens JWJ, Patel A, Vingerling JR et al (2009) Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetologia 52:2027–2036PubMedCrossRef
16.
Zurück zum Zitat The Diabetes Control and Complications Trial Research Group (1995) The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complication Trial. Diabetes 44:968–983CrossRef The Diabetes Control and Complications Trial Research Group (1995) The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complication Trial. Diabetes 44:968–983CrossRef
17.
Zurück zum Zitat Shichiri M, Kishikawa H, Ohkubo Y, Wake N, Mogensen CE, Pass P (2000) Long term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 23:B21–B29PubMed Shichiri M, Kishikawa H, Ohkubo Y, Wake N, Mogensen CE, Pass P (2000) Long term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 23:B21–B29PubMed
18.
Zurück zum Zitat Stratton IM, Kohner EM, Aldington SJ et al (2001) UKPDS 50: risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Diabetologia 44:156–163PubMedCrossRef Stratton IM, Kohner EM, Aldington SJ et al (2001) UKPDS 50: risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Diabetologia 44:156–163PubMedCrossRef
19.
Zurück zum Zitat Ohkubo Y, Kishikawa H, Araki E et al (1995) Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103–117PubMedCrossRef Ohkubo Y, Kishikawa H, Araki E et al (1995) Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103–117PubMedCrossRef
20.
Zurück zum Zitat Kohner EM, Aldington SJ, Stratton IM et al (1998) United Kingdom Prospective Diabetes Study, 30: diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors. Arch Ophthalmol 116:297–303PubMedCrossRef Kohner EM, Aldington SJ, Stratton IM et al (1998) United Kingdom Prospective Diabetes Study, 30: diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors. Arch Ophthalmol 116:297–303PubMedCrossRef
21.
Zurück zum Zitat Porta M, Sjoelie AK, Chaturvedi N et al (2001) Risk factors for progression to proliferative diabetic retinopathy in the EURODIAB Prospective Complications Study. Diabetologia 44:2203–2209PubMedCrossRef Porta M, Sjoelie AK, Chaturvedi N et al (2001) Risk factors for progression to proliferative diabetic retinopathy in the EURODIAB Prospective Complications Study. Diabetologia 44:2203–2209PubMedCrossRef
22.
Zurück zum Zitat Klein R, Klein BE, Moss SE, Davis MD, DeMets DL (1984) The Wisconsin Epidemiologic Study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 102:527–532PubMedCrossRef Klein R, Klein BE, Moss SE, Davis MD, DeMets DL (1984) The Wisconsin Epidemiologic Study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 102:527–532PubMedCrossRef
23.
Zurück zum Zitat Suzuki K, Watanabe K, Motegi T, Kajinuma H (1989) High prevalence of proliferative retinopathy in diabetic patients with low pancreatic B cell capacity. Diabetes Res Clin Pract 6:45–53PubMedCrossRef Suzuki K, Watanabe K, Motegi T, Kajinuma H (1989) High prevalence of proliferative retinopathy in diabetic patients with low pancreatic B cell capacity. Diabetes Res Clin Pract 6:45–53PubMedCrossRef
24.
Zurück zum Zitat Steffes MW, Sibley S, Jackson M, Thomas W (2003) Beta-cell function and the development of diabetes-related complication in the Diabetes Control and Complications Trial. Diabetes Care 26:832–836PubMedCrossRef Steffes MW, Sibley S, Jackson M, Thomas W (2003) Beta-cell function and the development of diabetes-related complication in the Diabetes Control and Complications Trial. Diabetes Care 26:832–836PubMedCrossRef
25.
Zurück zum Zitat Kim BY, Jung CH, Mok JO, Kang SK, Kim CH (2012) Association between serum C-peptide levels and chronic microvascular complications in Korean type 2 diabetic patients. Acta Diabetol 49:9–15PubMedCrossRef Kim BY, Jung CH, Mok JO, Kang SK, Kim CH (2012) Association between serum C-peptide levels and chronic microvascular complications in Korean type 2 diabetic patients. Acta Diabetol 49:9–15PubMedCrossRef
26.
Zurück zum Zitat Inukai T, Matsutomo R, Tayama K, Aso Y, Takemora Y (1999) Relation between the serum level of C-peptide and risk factors for coronary heart disease and diabetic microangiopathic patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 107:40–45PubMedCrossRef Inukai T, Matsutomo R, Tayama K, Aso Y, Takemora Y (1999) Relation between the serum level of C-peptide and risk factors for coronary heart disease and diabetic microangiopathic patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 107:40–45PubMedCrossRef
27.
Zurück zum Zitat Cifarelli V, Geng X, Styche A, Lakomy R, Trucco M, Luppi P (2011) C-peptide reduces high-glucose-induced apoptosis of endothelial cells and decreases NAD(P)H-oxidase reactive oxygen species generation in human aortic endothelial cells. Diabetologia 54:2702–2712PubMedCrossRef Cifarelli V, Geng X, Styche A, Lakomy R, Trucco M, Luppi P (2011) C-peptide reduces high-glucose-induced apoptosis of endothelial cells and decreases NAD(P)H-oxidase reactive oxygen species generation in human aortic endothelial cells. Diabetologia 54:2702–2712PubMedCrossRef
Metadaten
Titel
Association of blood glucose control and pancreatic reserve with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT)
verfasst von
Nasrin Azad
Lily Agrawal
Nicholas V. Emanuele
Ronald Klein
Gideon D. Bahn
Peter Reaven
and The VADT Study Group
Publikationsdatum
01.06.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Diabetologia / Ausgabe 6/2014
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-014-3199-7

Weitere Artikel der Ausgabe 6/2014

Diabetologia 6/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.